Cochlear (COH) Panoramica del titolo
Cochlear Limited fornisce soluzioni uditive impiantabili per bambini e adulti in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 3/6 |
COH Community Fair Values
Create NarrativeSee what 66 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
AU$70
FV
39.3% sopravvalutato sconto intrinseco0.14%
Revenue growth p.a.
106
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
3users have followed this narrative
Concorrenti di Cochlear Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | AU$97.53 |
| Massimo di 52 settimane | AU$319.56 |
| Minimo di 52 settimane | AU$88.74 |
| Beta | 0.24 |
| Variazione di 1 mese | -2.06% |
| Variazione a 3 mesi | -50.93% |
| Variazione di 1 anno | -63.66% |
| Variazione a 3 anni | -60.19% |
| Variazione a 5 anni | -56.70% |
| Variazione dall'IPO | 3,206.10% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • May 09
COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds
The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.
Nuova narrazione • May 09
Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Recent updates
Aggiornamento della narrazione • May 09
COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds
The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.Nuova narrazione • May 09
Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Aggiornamento della narrazione • Apr 21
COH: VA Access Expansion Will Support Future Upside Despite Slight Model Adjustments
The Analyst Price Target for Cochlear has been adjusted slightly lower to A$239.95 from A$244.58, as analysts now factor in modestly softer revenue growth, profit margin and future P/E assumptions, along with a slightly higher discount rate. Valuation Changes Fair Value: adjusted slightly lower from A$244.58 to A$239.95.Aggiornamento della narrazione • Apr 04
COH: VA Access Expansion And Upgraded Coverage Will Underpin Future Upside
Analysts have slightly adjusted their price target for Cochlear to A$244.58 from A$245.91. This reflects updated assumptions around discount rates and valuation multiples, while core growth and profitability expectations remain broadly unchanged.Aggiornamento della narrazione • Mar 21
COH: VA Access Expansion Will Support Future Upside Potential
Analysts have adjusted their price target on Cochlear slightly lower to A$245.91 from A$250.59, reflecting modest tweaks to assumptions around the discount rate, revenue growth, profit margins and future P/E following recent research updates. Analyst Commentary Bullish Takeaways Bullish analysts see the revised A$245.91 target as still supportive of upside potential relative to recent trading levels, suggesting the core earnings story remains intact despite the small adjustment.Aggiornamento della narrazione • Mar 06
COH: Steady Assumptions And New Access Channels Will Support Future Upside Potential
Analysts have reaffirmed their A$250.59 price target for Cochlear, citing recent research that supports steady assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research behind the reaffirmed A$250.59 price target highlights a mix of supportive factors and watchpoints that matter for Cochlear's valuation and execution risk.
Nuova narrazione • Mar 01
Cloud And R&D Investment Will Pressure Margins While Long Term Hearing Demand Supports Stability
Catalysts About Cochlear Cochlear develops and manufactures hearing implant systems for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Feb 20
COH: Reset Expectations And Product Adoption Will Support Future Upside Potential
Analysts have trimmed their Cochlear price target from A$301.76 to A$250.59 as they factor in slightly lower revenue growth assumptions, a marginally higher discount rate, modestly softer profit margin expectations and a reduced future P/E multiple, as highlighted in recent Street research, including the latest upgrade at RBC Capital. Analyst Commentary Recent Street commentary around Cochlear focuses on how current expectations stack up against its A$250.59 target price and what needs to go right, or wrong, for that valuation to hold.Articolo di analisi • Feb 16
Cochlear (ASX:COH) Has Affirmed Its Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of April. This means...Articolo di analisi • Feb 15
Some Confidence Is Lacking In Cochlear Limited (ASX:COH) As Shares Slide 26%
Cochlear Limited ( ASX:COH ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Nuova narrazione • Feb 13
Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion
Catalysts About Cochlear Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Feb 06
Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Aggiornamento della narrazione • Feb 05
COH: Execution Upside And Premium P/E Will Underpin Future Upside Potential
Analysts have trimmed their price target on Cochlear to about A$302 from roughly A$305, reflecting a slightly higher discount rate, modestly lower revenue growth assumptions, and a small uplift in expected profit margins and future P/E multiples. Analyst Commentary Recent research adjustments on Cochlear point to a generally constructive stance, with the trimmed price target tied to updated assumptions rather than a material change in the long term story.Articolo di analisi • Jan 11
Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Articolo di analisi • Nov 18
Risks To Shareholder Returns Are Elevated At These Prices For Cochlear Limited (ASX:COH)
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...Articolo di analisi • Oct 14
Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Sep 28
We Think Cochlear (ASX:COH) Might Have The DNA Of A Multi-Bagger
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Aggiornamento della narrazione • Sep 19
Aging Population Will Spur Cochlear Implant Adoption Worldwide
Cochlear’s modestly lower consensus price target predominantly reflects a slight reduction in forecast revenue growth, resulting in a revised fair value estimate of A$305.38. What's in the News Cochlear extended its share buyback plan duration to August 28, 2026.Articolo di analisi • Aug 26
Cochlear (ASX:COH) Is Due To Pay A Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of October. This...Aggiornamento della narrazione • Aug 19
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91. What's in the News FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.Articolo di analisi • Jul 16
Cochlear Limited's (ASX:COH) Shares May Have Run Too Fast Too Soon
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Articolo di analisi • Jun 13
Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • May 26
Why You Should Care About Cochlear's (ASX:COH) Strong Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...Articolo di analisi • Apr 05
Unpleasant Surprises Could Be In Store For Cochlear Limited's (ASX:COH) Shares
Cochlear Limited's ( ASX:COH ) price-to-earnings (or "P/E") ratio of 46.1x might make it look like a strong sell right...Articolo di analisi • Mar 06
Cochlear (ASX:COH) Will Pay A Larger Dividend Than Last Year At A$2.15
Cochlear Limited's ( ASX:COH ) dividend will be increasing from last year's payment of the same period to A$2.15 on...Articolo di analisi • Feb 23
Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Nuova narrazione • Feb 23
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.Articolo di analisi • Feb 08
Is Cochlear Limited (ASX:COH) Worth AU$310 Based On Its Intrinsic Value?
Key Insights The projected fair value for Cochlear is AU$247 based on 2 Stage Free Cash Flow to Equity Current share...Articolo di analisi • Dec 20
Earnings Not Telling The Story For Cochlear Limited (ASX:COH)
Cochlear Limited's ( ASX:COH ) price-to-earnings (or "P/E") ratio of 53x might make it look like a strong sell right...Articolo di analisi • Nov 19
Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...Articolo di analisi • Nov 04
Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights The projected fair value for Cochlear is AU$234 based on 2 Stage Free Cash Flow to Equity Cochlear's...Articolo di analisi • Oct 18
We Think Shareholders May Consider Being More Generous With Cochlear Limited's (ASX:COH) CEO Compensation Package
Key Insights Cochlear's Annual General Meeting to take place on 25th of October Total pay for CEO Dig Howitt includes...Articolo di analisi • Sep 19
Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 19x, you may consider...Articolo di analisi • Aug 16
Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next
Cochlear Limited ( ASX:COH ) shareholders are probably feeling a little disappointed, since its shares fell 5.4% to...Articolo di analisi • Aug 01
Investors Could Be Concerned With Cochlear's (ASX:COH) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Articolo di analisi • Jun 08
Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Articolo di analisi • Mar 27
Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Articolo di analisi • Feb 21
Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Dec 18
Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to...Articolo di analisi • Oct 04
Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights The projected fair value for Cochlear is AU$192 based on 2 Stage Free Cash Flow to Equity Current share...Articolo di analisi • Sep 12
Cochlear (ASX:COH) Could Be Struggling To Allocate Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Rendimenti per gli azionisti
| COH | AU Medical Equipment | AU Mercato | |
|---|---|---|---|
| 7D | 1.2% | 2.7% | -0.4% |
| 1Y | -63.7% | -44.3% | 2.9% |
Ritorno vs Industria: COH ha avuto una performance inferiore rispetto al Australian Medical Equipment che ha registrato un rendimento -44.3 % nell'ultimo anno.
Rendimento vs Mercato: COH ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 2.9 % nell'ultimo anno.
Volatilità dei prezzi
| COH volatility | |
|---|---|
| COH Average Weekly Movement | 12.3% |
| Medical Equipment Industry Average Movement | 10.6% |
| Market Average Movement | 10.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 4.4% |
Prezzo delle azioni stabile: COH non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Australian.
Volatilità nel tempo: La volatilità settimanale di COH è aumentata da 7% a 12% nell'ultimo anno, ma è ancora inferiore al 75% delle azioni Australian.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1981 | 5,500 | Dig Howitt | www.cochlear.com |
Cochlear Limited fornisce soluzioni uditive impiantabili per bambini e adulti in tutto il mondo. L'azienda offre sistemi di impianti cocleari, aggiornamenti degli elaboratori del suono, sistemi di conduzione ossea e altri prodotti. Fornisce anche sistemi cocleari Nucleus, tra cui gli elaboratori del suono Nucleus, la soluzione uditiva bimodale intelligente e gli impianti Nucleus; sistemi cocleari Baha, tra cui l'elaboratore del suono Baha 6 max e l'impianto Baha; e accessori, come i dispositivi wireless e gli accessori Nucleus water-safe.
Cochlear Limited Riepilogo dei fondamenti
| COH statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | AU$6.38b |
| Utili (TTM) | AU$345.30m |
| Ricavi(TTM) | AU$2.34b |
18.5x
Rapporto P/E2.7x
Rapporto P/SCOH è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| COH Conto economico (TTM) | |
|---|---|
| Ricavi | AU$2.34b |
| Costo del fatturato | AU$636.90m |
| Profitto lordo | AU$1.70b |
| Altre spese | AU$1.36b |
| Utili | AU$345.30m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Aug 18, 2026
| Utile per azione (EPS) | 5.28 |
| Margine lordo | 72.76% |
| Margine di profitto netto | 14.77% |
| Rapporto debito/patrimonio netto | 0.7% |
Come si è comportato COH nel lungo periodo?
Vedi performance storica e confrontoDividendi
4.4%
Rendimento attuale del dividendo81%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/22 20:44 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/06/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cochlear Limited è coperta da 26 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Stuart Roberts | Bell Potter |
| Elisabeth Decou Clive | Bernstein |